Targeting the CCL2-CCR2 signaling axis in cancer metastasis.

Lim SY, Yuzhalin AE, Gordon-Weeks AN, Muschel RJ. · 2016

Read Targeting the CCL2-CCR2 signaling axis in cancer metastasis. by Lim SY, Yuzhalin AE, Gordon-Weeks AN, Muschel RJ. (2016) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5053756.txt.

Description

Su Yin Lim, Arseniy E. Yuzhalin, Alex N. Gordon-Weeks, and Ruth J. Muschel review a chemokine pathway in Oncotarget in 2016. CCL2 is a signal that calls in immune and support cells, and its receptor CCR2 sits on many of them. Tumors exploit the pair to grow blood vessels, recruit helper cells, and spread to distant organs, which made the pathway a tempting drug target.

The review traces the pair's roles step by step through metastasis, from tumor growth to the seeding of new sites. It then weighs the clinical trials that blocked CCL2 or CCR2 in solid and metastatic cancers. Results so far disappoint: blocking the signal can trigger a rebound rise in CCL2 itself, and sister signals may cover the gap. The authors urge closer reading of trial data to find patient groups or schedules where blockade might still earn its place.

Catalog record

CREATORLim SY, Yuzhalin AE, Gordon-Weeks AN, Muschel RJ.
YEAR2016
COLLECTIONPAPERS
FORMATTXT
FILE SIZE66 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC5053756

Browse the full library · About the Tower of Babel